Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 126-130

  Dietrich III, Charles S ^a   Greenberg, Victoria L ^b   DeSimone, Christopher P ^b   Modesitt, Susan C ^c   van Nagell, John R ^b   Craven, Rolf ^b   Zimmer, Stephen G ^b  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bad; Histone deacetylase inhibitor; Ovarian cancer; Paclitaxel; SAHA; Survivin

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAD; SURVIVIN; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN B; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 70749118328     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.039     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23 5 Suppl. 12 (1996) 40-47
3. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 9 (2000) 699-708
4. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 15 (2000) 1210-1216
5. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 6 (2002) 415-428
6. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 3 (2001) 194-202
7. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 6 (2001) 477-483
8. Marks P.A., Rifkind R.A., Richon V.M., and Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7 4 (2001) 759-760
9. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 4 (2002) 287-299
10. Rosato R.R., and Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther. 2 1 (2003) 30-37
11. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 13 1 (2002) 1-13
12. Garcia-Manero G., and Issa J.P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 23 7 (2005) 635-642
13. Grant S., Easley C., and Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov. 6 (2007) 21-22
14. Kelly W.K., Richon V.M., O'Connor O., Curley T., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003) 3578-3588
15. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
16. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
17. Chobanian N.H., Greenberg V.L., Gass J.M., DeSimone C.P., van Nagell J.R., and Zimmer S.G. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res. 24 (2004) 539-545
18. Cooper A.L., Greenberg V.L., Lancaster P.S., van Nagell J.R., and Zimmer S.G. Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. 104 (2007) 596-601
19. DeSimone C.P., Greenberg V.L., Chobanian N.H., van Nagell J.R., and Zimmer S.G. The combined and in vitro effects of paclitaxel and histone deacetylase inhibitors on ovarian cancer. Proc. Amer. Assoc. Cancer Res. 44 (2003) 217
20. Takai N., Kawamata N., Gui D., Said J.W., Miyakawa I., and Koeffler H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potentially induce apoptosis. Cancer 101 12 (2004) 2760-2770
21. Modesitt S.C., Sill M., Hoffman J.S., and Bender D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109 2 (2008) 182-186
22. Dowdy S.C., Jiang S., Zhou X.C., Hou X., Jin F., Podratz K.C., et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther. 5 11 (2006) 2767-2776
23. Sonnemann J., Gange J., Pilz S., Stotzer C., Ohlinger R., Belau A., et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6 (2006) 183-191
24. De Shepper S., Bruwiere H., Verhulst T., Steller U., Andries L., Wouters W., et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of surviving. J. Pharmaco. Exper. Ther. 304 2 (2003) 881-888
25. Strait K.A., Warnick C.T., Ford C.D., Dabbas B., Hammond E.H., and Ilstrup S.J. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol. Cancer Ther. 4 4 (2005) 603-611
26. Alteri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 1 (2003) 46-54
27. Yoshida H., Ishiko O., Sumi T., Matsumoto Y., and Ogita S. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int. J. Oncol. 19 (2001) 537-542
28. O'Conner D.S., Wall N.R., Porter A., and Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2 1 (2002) 43-54
29. Mollinedo F., and Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8 (2003) 413-450
30. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 396 6711 (1998) 580-584
31. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59 (2002) 1406-1412
32. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13103-13107
33. Mesri M., Wall N.R., Li J., Kim R., and Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108 (2001) 98-106
34. Grossman D., Kim P.J., Schechner J.S., and Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 635-640
35. Dedes K.J., Dedes I., Imesch P., von Bueren A.O., et al. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with lossof histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anti-Cancer Drugs 20 5 (2009) 321-333